UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000018162
Receipt number R000021036
Scientific Title Randomized phase II study of clinical effect of ghrelin administration for DCF with esophageal cancer patients
Date of disclosure of the study information 2015/07/02
Last modified on 2016/07/12 10:17:43

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Randomized phase II study of clinical effect of ghrelin administration for DCF with esophageal cancer patients

Acronym

Randomized phase II study of clinical effect of ghrelin administration for DCF with esophageal cancer patients

Scientific Title

Randomized phase II study of clinical effect of ghrelin administration for DCF with esophageal cancer patients

Scientific Title:Acronym

Randomized phase II study of clinical effect of ghrelin administration for DCF with esophageal cancer patients

Region

Japan


Condition

Condition

patients with esophageal cancer, undergoing chemotherapy

Classification by specialty

Gastroenterology Hematology and clinical oncology Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate safety and effectiveness of exogenous ghrelin administration for reducing renal toxicity in esophageal cancer patients with DCF.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

serum creatinine level

Key secondary outcomes

adverse events
serum cystatin C level
hormone measurement (ghrelin, growth hormone, Insulin-like growth factor-1)
outcomes of 2nd cycle chemotherapy


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

Placebo

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

In ghrelin group (n=20), patients with esophageal cancer were recieved intravenous synthetic human ghrelin (0.5 micro g/kg/h) administration for 5 days from a day ago of DCF.

Interventions/Control_2

In control group (n=20), patients with esophageal cancer were received intravenous D-mannitol (178.5 micro g/kg/h) administration for 5 days from a day ago of DCF.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

1. patients with primary esophageal cancer planned DCF chemotherapy;
2. creatinine clearance > 60 ml/min;
3. No renal disease;
4. no previous treatment;
5. age; 20-80 years;
6. adequate function of major organs;
7. Eastern Cooperative Oncology Group performance status (PS) score of 0 or 1;
8. provision of written informed consent

Key exclusion criteria

1. Patients with severe co morbid conditions
2. other active malignancy
3. judged as inappropriate by physician-in-charge
4. combination with radiation therapy
5. lactation and pregnancy

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shuji Takiguchi

Organization

Osaka University School of Medicine

Division name

Gastroenterological Surgery

Zip code


Address

Yamadaoka 2-2 E2, Suita-city, Osaka

TEL

06-6879-3251

Email

stakiguchi@gesurg.med.osaka-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yoshitomo Yanagimoto

Organization

Osaka University School of Medicine

Division name

Gastroenterological Surgery

Zip code


Address

Yamadaoka 2-2 E2, Suita-city, Osaka

TEL

06-6879-3251

Homepage URL


Email

yoshitomo-0225@outlook.com


Sponsor or person

Institute

Osaka University School of Medicine Gastroenterological Surgery

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 07 Month 02 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

http://www.nature.com/bjc/journal/v114/n12/full/bjc2016160a.html

Number of participants that the trial has enrolled


Results

Blood acyl ghrelin, total ghrelin, and IGF-1 concentrations on day 4 were significantly higher in the ghrelin group. The renal dysfunction, serum creatinine and cystatin C levels, dose reduction, and delay in the initiation of the second cycle of chemotherapy were lower in the ghrelin group than in the control group. Serum creatinine levels were significantly correlated with serum IGF-1 levels.

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 05 Month 01 Day

Date of IRB


Anticipated trial start date

2014 Year 06 Month 09 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 07 Month 02 Day

Last modified on

2016 Year 07 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021036


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name